Evidence map›Paper›PMID 42225614›Full record

ArticleCell death & disease2026

Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo.

Matteo Cassandri, Antonella Porrazzo, Simona Camero, Silvia Pomella, Valeria Manzi, Francesca Vulcano, Luisa Milazzo, Francesca Pedini, Deborah Pajalunga, Andrea Casagrande and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Matteo CassandriDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
Antonella PorrazzoDepartment of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy.
Simona CameroDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
Silvia PomellaDepartment of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Valeria ManziDepartment of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy.
Francesca VulcanoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Luisa MilazzoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Francesca PediniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Deborah PajalungaDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Andrea CasagrandeDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.ORCID http://orcid.org/0000-0003-3400-7609
Giada MeleDepartment of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy.
Valentina LulliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Enrico RomanoDepartment of Sense Organs, Sapienza University of Rome, Rome, Italy.
Michele SignoreRPPA Unit, Proteomics Area, Core Facilities, Istituto Superiore di Sanità, Rome, Italy.ORCID http://orcid.org/0000-0002-0262-842X
Massimo SpadaCenter of Animal Research and Welfare, Istituto Superiore di Sanità, Rome, Italy.
Maria Teresa D'UrsoCenter of Animal Research and Welfare, Istituto Superiore di Sanità, Rome, Italy.
Silvia CodenottiDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Alessandro FanzaniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Annunziata MauroFaculty of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
Giovanna MarcheseGenomix4Life S.r.l, Baronissi, Italy.
Simone SidoliDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
Giovanni Luca GravinaDepartment of Biotechnological and Applied Clinical Sciences, Radiation Oncology Unit, Ospedale San Salvatore, University of L'Aquila, L'Aquila, Italy.
Giovanni BarillariDepartment of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy.
Franco LocatelliDepartment of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-7976-3654
Francesca MegiorniDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy. francesca.megiorni@uniroma1.it.ORCID http://orcid.org/0000-0003-3705-3248
Rossella RotaDepartment of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-9408-7711
Francesco MaramponDepartment of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy. francesco.marampon@uniroma1.it.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG#24696Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG#27794Fondazione Italiana per la Ricerca sul Cancro (Italian Foundation for Cancer Research) IG#15312Ministero della Salute (Ministry of Health, Italy) Ricerca Finalizzata GR-2021-12374415NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS), a pediatric soft tissue sarcoma, comprises two major subtypes: fusion-positive (FP), driven by PAX3/7-FOXO1 fusions, and fusion-negative (FN), often harboring RAS pathway mutations. High-risk RMS exhibits intrinsic resistance to radiotherapy (RT), posing a significant clinical hurdle. Emerging evidence implicates EZH2, the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), in promoting RT resistance through gene silencing via H3K27me3. To dissect the molecular basis of RMS radioresistance, we employed an integrative multi-omics approach encompassing phosphoproteomics and transcriptomics. Radioresistant RMS cell models (RMS

Indexed as

BenzamidesBiphenyl CompoundsCarbamatesEnhancer of Zeste Homolog 2 ProteinMorpholinesPyridinesPyridonesRadiation-Sensitizing AgentsRadiation ToleranceRhabdomyosarcomaAnimalsApoptosisCell Line, TumorHumansMiceMultiomicsBenzamidesBiphenyl CompoundsCarbamatesEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMorpholinesPyridinesPyridonesRadiation-Sensitizing Agentstazemetostat

Identifiers

PMID42225614
PMCPMC13439469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.